1. Utilizing MRD Assessment in Community Practice

3. Content Outline

4. Why Test MRD?

5. What Do Community Oncologists Need to Consider for MRD Testing?

6. Methods for MRD Assessment[a-d]

7. Are 2 MRD Tests Better Than 1?

8. Can We Inform Treatment Decisions Using MRD Assessment?

9. How to Decide on Which Test to Order

10. Managing Barriers to MRD Testing in the Community

11. MRD in CLL

12. MRD in CLL General Considerations

13. MURANO Data Post-Treatment Follow-Up

14. CLL14 Obinutuzumab ± Venetoclax vs Chlorambucil in Untreated CLL

15. MRD in Multiple Myeloma

16. MRD in MM General Considerations

17. Optimal Timing of MRD Assessment in MM Results From PRiMER

18. Is There a Role for Serial MRD Testing in Practice?

19. MRD in AML

20. CHRYSALIS Trial Data

21. ADMIRAL Trial Data

22. FLT3-Positive AML A Focus on MRD Negativity

23. MRD in ALL

24. BLAST Study Rationale

25. BLAST Study Results

26. Implications of Trial Data for Community Hematology Practices

27. Remaining Questions for MRD Testing

28. Concluding Remarks

29. Abbreviations

30. Abbreviations (cont)